<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03216980</url>
  </required_header>
  <id_info>
    <org_study_id>HM20009929</org_study_id>
    <nct_id>NCT03216980</nct_id>
  </id_info>
  <brief_title>Examining the Effect of Posttraumatic Stress Disorder on Vascular Function and Exercise Tolerance</brief_title>
  <official_title>Examining the Effect of Posttraumatic Stress Disorder on Vascular Function and Exercise Tolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Specific Aim #1: Examining the impact of posttraumatic stress disorder (PTSD) on peripheral
      vascular function and sympathetic nervous system activity in young individuals.

      Specific Aim #2: Examining the impact of posttraumatic stress disorder (PTSD) on peripheral
      hemodynamics and metabolic byproducts during small muscle mass exercise in young individuals.

      Specific Aim #3: Examining the impact of posttraumatic stress disorder (PTSD) on exercise
      tolerance, peripheral hemodynamics and metabolic byproducts during large muscle mass exercise
      in young individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post-traumatic stress disorder (PTSD) is a disabling psychiatric condition characterized by a
      persistent maladaptive reaction resulting from exposure to severe psychological stress. It
      has been revealed that individuals with PTSD, in addition to adverse mental health symptoms,
      also possess higher prevalence rates for physical comorbidities such as hypertension,
      obesity, diabetes, and metabolic syndrome. Taken together, these PTSD-induced comorbidities
      result in a significant increase in the likelihood of developing cardiovascular disease (CVD)
      when compared to individuals without PTSD. Peripheral vascular dysfunction, or the inability
      of the blood vessels to adequately respond to specific stimuli, is a factor closely related
      to CVD. Therefore, this study will focus on a younger population with PTSD in an attempt to
      ascertain the presence of peripheral vascular dysfunction and the magnitude to which two
      potential primary contributors (autonomic dysfunction, oxidative stress) are involved in this
      dysfunction.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2017</start_date>
  <completion_date type="Anticipated">May 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arm Vascular Function at Rest (Flow Mediated Dilation Test) and in Response to Exercise (Handgrip Exercise Test)</measure>
    <time_frame>Before and Immediately After Intervention</time_frame>
    <description>Change in Brachial Artery Dilation from Baseline Values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Leg Vascular Function (Passive Leg Movement Test)</measure>
    <time_frame>Before and Immediately After Intervention</time_frame>
    <description>Change in Leg Blood Flow Values from Baseline</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Post Traumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>PTSD Antioxidant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTSD Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will ingest placebo (microcrystalline cellulose) pills.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control Antioxidant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will ingest placebo (microcrystalline cellulose) pills.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PTSD Antioxidant</intervention_name>
    <description>Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).</description>
    <arm_group_label>PTSD Antioxidant</arm_group_label>
    <arm_group_label>PTSD Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PTSD Placebo</intervention_name>
    <description>Subjects will ingest placebo (microcrystalline cellulose) pills.</description>
    <arm_group_label>PTSD Antioxidant</arm_group_label>
    <arm_group_label>PTSD Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Healthy Control Antioxidant</intervention_name>
    <description>Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).</description>
    <arm_group_label>Healthy Control Antioxidant</arm_group_label>
    <arm_group_label>Healthy Control Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Healthy Control Placebo</intervention_name>
    <description>Subjects will ingest placebo (microcrystalline cellulose) pills.</description>
    <arm_group_label>Healthy Control Antioxidant</arm_group_label>
    <arm_group_label>Healthy Control Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  apparently healthy and free of overt cardiovascular, pulmonary, or metabolic disease

          -  for PTSD group, a score of â‰¥ 40 on PTSD checklist

        Exclusion Criteria:

          -  taking medications that could influence cardiovascular function

          -  limited English proficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Garten, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ryan Garten, PhD</last_name>
    <phone>(804) 828-1948</phone>
    <email>rsgarten@vcu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2017</study_first_submitted>
  <study_first_submitted_qc>July 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2017</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiovascular disease</keyword>
  <keyword>vascular function</keyword>
  <keyword>PTSD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>Thioctic Acid</mesh_term>
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

